schliessen

Filtern

 

Bibliotheken

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

The treatment of advanced renal cell carcinoma has been revolutionised by targeted therapy with drugs that block angiogenesis. So far, no phase 3 randomised trials comparing the effectiveness of one targeted agent against another have been reported. We did a randomised phase 3 study comparing axitin... Full description

Journal Title: The Lancet 2011, Vol.378(9807), pp.1931-1939
Main Author: Rini, Brian I
Other Authors: Escudier, Bernard , Tomczak, Piotr , Kaprin, Andrey , Szczylik, Cezary , Hutson, Thomas E , Michaelson, M Dror , Gorbunova, Vera A , Gore, Martin E , Rusakov, Igor G , Negrier, Sylvie , Ou, Yen-Chuan , Castellano, Daniel , Lim, Ho Yeong , Uemura, Hirotsugu , Tarazi, Jamal , Cella, David , Chen, Connie , Rosbrook, Brad , Kim, Sinil
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0140-6736 ; E-ISSN: 1474-547X ; DOI: 10.1016/S0140-6736(11)61613-9
Link: https://www.sciencedirect.com/science/article/pii/S0140673611616139
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_S0140_6736_11_61613_9
title: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
format: Article
creator:
  • Rini, Brian I
  • Escudier, Bernard
  • Tomczak, Piotr
  • Kaprin, Andrey
  • Szczylik, Cezary
  • Hutson, Thomas E
  • Michaelson, M Dror
  • Gorbunova, Vera A
  • Gore, Martin E
  • Rusakov, Igor G
  • Negrier, Sylvie
  • Ou, Yen-Chuan
  • Castellano, Daniel
  • Lim, Ho Yeong
  • Uemura, Hirotsugu
  • Tarazi, Jamal
  • Cella, David
  • Chen, Connie
  • Rosbrook, Brad
  • Kim, Sinil
subjects:
  • Medicine
ispartof: The Lancet, 2011, Vol.378(9807), pp.1931-1939
description: The treatment of advanced renal cell carcinoma has been revolutionised by targeted therapy with drugs that block angiogenesis. So far, no phase 3 randomised trials comparing the effectiveness of one targeted agent against another have been reported. We did a randomised phase 3 study comparing axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor (VEGF) receptors, with sorafenib, an approved VEGF receptor inhibitor, as second-line therapy in patients with metastatic renal cell cancer. We included patients coming from 175 sites (hospitals and outpatient clinics) in 22 countries aged 18 years or older with confirmed renal clear-cell carcinoma who progressed despite first-line therapy containing sunitinib, bevacizumab plus interferon-alfa, temsirolimus, or cytokines. Patients were stratified according to Eastern Cooperative Oncology Group performance status and type of previous treatment and then randomly assigned (1:1)...
language: eng
source:
identifier: ISSN: 0140-6736 ; E-ISSN: 1474-547X ; DOI: 10.1016/S0140-6736(11)61613-9
fulltext: fulltext
issn:
  • 0140-6736
  • 01406736
  • 1474-547X
  • 1474547X
url: Link


@attributes
ID195430372
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_S0140_6736_11_61613_9
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_S0140_6736_11_61613_9
sourcesystemPC
dbid
0--K
1--M
2.FO
31B1
41P~
51RT
6457
74G.
87-5
99JM
10AABNK
11AAEDT
12AAQFI
13ABBQC
14ABFNM
15ABMZM
16ABYKQ
17ACIUM
18ACRLP
19AEKER
20AEVXI
21AFKWA
22AFTJW
23AFXIZ
24AGHFR
25AHHHB
26AITUG
27AJBFU
28AJOXV
29AJRQY
30AJUYK
31AMFUW
32ANZVX
33BNPGV
34EO8
35EO9
36EP2
37EP3
38FDB
39FGOYB
40FIRID
41FNPLU
42G-Q
43GBLVA
44J1W
45KOM
46OD.
47OO~
48P-8
49P-9
50PC.
51R2-
52RPZ
53SAD
54SDF
55SDG
56SEL
57SES
58SSH
59SSZ
60T5K
61UV1
62Z5R
pqid908743327
galeid341836440
display
typearticle
titleComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
creatorRini, Brian I ; Escudier, Bernard ; Tomczak, Piotr ; Kaprin, Andrey ; Szczylik, Cezary ; Hutson, Thomas E ; Michaelson, M Dror ; Gorbunova, Vera A ; Gore, Martin E ; Rusakov, Igor G ; Negrier, Sylvie ; Ou, Yen-Chuan ; Castellano, Daniel ; Lim, Ho Yeong ; Uemura, Hirotsugu ; Tarazi, Jamal ; Cella, David ; Chen, Connie ; Rosbrook, Brad ; Kim, Sinil
ispartofThe Lancet, 2011, Vol.378(9807), pp.1931-1939
identifier
subjectMedicine
descriptionThe treatment of advanced renal cell carcinoma has been revolutionised by targeted therapy with drugs that block angiogenesis. So far, no phase 3 randomised trials comparing the effectiveness of one targeted agent against another have been reported. We did a randomised phase 3 study comparing axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor (VEGF) receptors, with sorafenib, an approved VEGF receptor inhibitor, as second-line therapy in patients with metastatic renal cell cancer. We included patients coming from 175 sites (hospitals and outpatient clinics) in 22 countries aged 18 years or older with confirmed renal clear-cell carcinoma who progressed despite first-line therapy containing sunitinib, bevacizumab plus interferon-alfa, temsirolimus, or cytokines. Patients were stratified according to Eastern Cooperative Oncology Group performance status and type of previous treatment and then randomly assigned (1:1)...
languageeng
source
version10
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://www.sciencedirect.com/science/article/pii/S0140673611616139$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Rini, Brian I
1Escudier, Bernard
2Tomczak, Piotr
3Kaprin, Andrey
4Szczylik, Cezary
5Hutson, Thomas E
6Michaelson, M Dror
7Gorbunova, Vera A
8Gore, Martin E
9Rusakov, Igor G
10Negrier, Sylvie
11Ou, Yen-Chuan
12Castellano, Daniel
13Lim, Ho Yeong
14Uemura, Hirotsugu
15Tarazi, Jamal
16Cella, David
17Chen, Connie
18Rosbrook, Brad
19Kim, Sinil
titleComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
description

The treatment of advanced renal cell carcinoma has been revolutionised by targeted therapy with drugs that block angiogenesis. So far, no phase 3 randomised trials comparing the effectiveness of one targeted agent against another have been reported. We did a randomised phase 3 study comparing axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor (VEGF) receptors, with sorafenib, an approved VEGF receptor inhibitor, as second-line therapy in patients with metastatic renal cell cancer.

We included patients coming from 175 sites (hospitals and outpatient clinics) in 22 countries aged 18 years or older with confirmed renal clear-cell carcinoma who progressed despite first-line therapy containing sunitinib, bevacizumab plus interferon-alfa, temsirolimus, or cytokines. Patients were stratified according to Eastern Cooperative Oncology Group performance status and type of previous treatment and then randomly assigned (1:1)...

subjectMedicine
general
0English
1Elsevier Ltd
210.1016/S0140-6736(11)61613-9
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_S0140_6736_11_61613_9
issn
00140-6736
101406736
21474-547X
31474547X
rsrctypearticle
creationdate2011
addtitleThe Lancet
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
1--M
2.FO
31B1
41P~
51RT
6457
74G.
87-5
99JM
10AABNK
11AAEDT
12AAQFI
13ABBQC
14ABFNM
15ABMZM
16ABYKQ
17ACIUM
18ACRLP
19AEKER
20AEVXI
21AFKWA
22AFTJW
23AFXIZ
24AGHFR
25AHHHB
26AITUG
27AJBFU
28AJOXV
29AJRQY
30AJUYK
31AMFUW
32ANZVX
33BNPGV
34EO8
35EO9
36EP2
37EP3
38FDB
39FGOYB
40FIRID
41FNPLU
42G-Q
43GBLVA
44J1W
45KOM
46OD.
47OO~
48P-8
49P-9
50PC.
51R2-
52RPZ
53SAD
54SDF
55SDG
56SEL
57SES
58SSH
59SSZ
60T5K
61UV1
62Z5R
startdate20110101
enddate20111231
lsr40The Lancet, 2011, Vol.378 (9807), pp.1931-1939
doi10.1016/S0140-6736(11)61613-9
citationpf 1931 pt 1939 vol 378 issue 9807
lsr30VSR-Enriched:[date, galeid, pqid]
sort
titleComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
authorRini, Brian I ; Escudier, Bernard ; Tomczak, Piotr ; Kaprin, Andrey ; Szczylik, Cezary ; Hutson, Thomas E ; Michaelson, M Dror ; Gorbunova, Vera A ; Gore, Martin E ; Rusakov, Igor G ; Negrier, Sylvie ; Ou, Yen-Chuan ; Castellano, Daniel ; Lim, Ho Yeong ; Uemura, Hirotsugu ; Tarazi, Jamal ; Cella, David ; Chen, Connie ; Rosbrook, Brad ; Kim, Sinil
creationdate20110000
lso0120110000
facets
frbrgroupid4625533178017797623
frbrtype5
newrecords20190904
languageeng
topicMedicine
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Rini, Brian I
1Escudier, Bernard
2Tomczak, Piotr
3Kaprin, Andrey
4Szczylik, Cezary
5Hutson, Thomas E
6Michaelson, M Dror
7Gorbunova, Vera A
8Gore, Martin E
9Rusakov, Igor G
10Negrier, Sylvie
11Ou, Yen-Chuan
12Castellano, Daniel
13Lim, Ho Yeong
14Uemura, Hirotsugu
15Tarazi, Jamal
16Cella, David
17Chen, Connie
18Rosbrook, Brad
19Kim, Sinil
jtitleLancet
creationdate2011
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Rini
1Escudier
2Tomczak
3Kaprin
4Szczylik
5Hutson
6Michaelson
7Gorbunova
8Gore
9Rusakov
10Negrier
11Ou
12Castellano
13Lim
14Uemura
15Tarazi
16Cella
17Chen
18Rosbrook
19Kim
aufirst
0Brian I
1Bernard
2Piotr
3Andrey
4Cezary
5Thomas E
6M Dror
7Vera A
8Martin E
9Igor G
10Sylvie
11Yen-Chuan
12Daniel
13Ho Yeong
14Hirotsugu
15Jamal
16David
17Connie
18Brad
19Sinil
auinitB
auinit1B
au
0Rini, Brian I
1Escudier, Bernard
2Tomczak, Piotr
3Kaprin, Andrey
4Szczylik, Cezary
5Hutson, Thomas E
6Michaelson, M Dror
7Gorbunova, Vera A
8Gore, Martin E
9Rusakov, Igor G
10Negrier, Sylvie
11Ou, Yen-Chuan
12Castellano, Daniel
13Lim, Ho Yeong
14Uemura, Hirotsugu
15Tarazi, Jamal
16Cella, David
17Chen, Connie
18Rosbrook, Brad
19Kim, Sinil
atitleComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
jtitleThe Lancet
risdate2011
volume378
issue9807
spage1931
epage1939
pages1931-1939
issn0140-6736
eissn1474-547X
formatjournal
genrearticle
ristypeJOUR
abstract

The treatment of advanced renal cell carcinoma has been revolutionised by targeted therapy with drugs that block angiogenesis. So far, no phase 3 randomised trials comparing the effectiveness of one targeted agent against another have been reported. We did a randomised phase 3 study comparing axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor (VEGF) receptors, with sorafenib, an approved VEGF receptor inhibitor, as second-line therapy in patients with metastatic renal cell cancer.

We included patients coming from 175 sites (hospitals and outpatient clinics) in 22 countries aged 18 years or older with confirmed renal clear-cell carcinoma who progressed despite first-line therapy containing sunitinib, bevacizumab plus interferon-alfa, temsirolimus, or cytokines. Patients were stratified according to Eastern Cooperative Oncology Group performance status and type of previous treatment and then randomly assigned (1:1)...

pubElsevier Ltd
doi10.1016/S0140-6736(11)61613-9
lad01The Lancet
date2011-12-03